• where experts go to learn about FDA
  • Hyman Phelps McNamara

    • HP&M to Host Webinar on the FDA Appeals ProcessJanuary 19th, 2012

      Pharmaceutical and medical device applicants faced with an adverse decision from FDA (e.g., regarding data requirements, study design, or regulatory pathway) may dispute that decision through multiple routes.  The appeal processes in both CDER and CDRH offer numerous strategic and procedural advantages that, when used …

    • ACI’s FDA Boot Camp ConferenceJanuary 19th, 2012

      The American Conference Institute will be holding its FDA Boot Camp conference in New York City from Tuesday, March 20 to Wednesday, March 21, 2012.  A copy of the conference program can be obtained here.  Hyman, Phelps & McNamara, P.C.’s Kurt R. Karst will be …

    • FDA Sends User Fee Pacts to Congress; Proposed Generic Drug User Fee Statute Includes Some Unique ProvisionsJanuary 18th, 2012

      By Kurt R. Karst –       Last week, FDA Commissioner Margaret A. Hamburg, M.D. announced that the Agency sent to Congress packages for three user fee programs, including proposed statutory language for the fifth iteration of the Prescription Drug User Fee Act (“PDUFA V”), and two new …

    • Supreme Court To Decide When EPA and Perhaps Other Federal Agencies Can be Sued in Federal CourtJanuary 17th, 2012

      By JP Ellison – An important issue relating to when an action by an administrative agency can be challenged in court was argued before the Supreme Court last week.  The case involved administrative enforcement activities of the U.S. Environmental Protection Agency (“EPA”). The case, Sackett v. …

    • National Organic Program Proposes to Change Listing of Nutrients That Can be Added to Organic FoodJanuary 16th, 2012

      By Riëtte van Laack – USDA’s National Organic Program ("NOP") published a proposed rule that would amend the listing of vitamins and minerals in the National List of Allowed and Prohibited Substances (National List).  The National List identifies non-agricultural synthetic ingredients that may be used in …

    • FDA Denies Petition Seeking to Add Application Information to Drug LabelsJanuary 12th, 2012

      By Kurt R. Karst –       FDA recently denied a 2008 citizen petition (Docket No. FDA-2008-P-0291) requesting that the Agency amend its drug label regulations to require that product labels include the Orange Book-listed NDA number under which the product is approved.  According to the petition, “[i]ncreasingly, …

    • FDA Publishes Order Prohibiting the Extralabel Use of Antimicrobial Cephalosporins in Food-producing Major SpeciesJanuary 11th, 2012

      By Riëtte van Laack – The Animal Medicinal Drug Use Clarification Act of 1994 (“AMDUCA”) amended the FDC Act § 512(a) allowing veterinarians to prescribe extralabel use of certain approved animal and human drugs for animals.  (Extralabel use includes use in species not listed in the …

    • Senators Hatch and Harkin Request that FDA Withdraw Draft NDI GuidanceJanuary 10th, 2012

      By Riëtte van Laack – In a strongly worded letter to FDA Commissioner Hamburg dated December 22, 2011, the principal authors of the Dietary Supplement Health and Education Act of 1994 (“DSHEA”), Senators Orrin Hatch (R-UT) and Tom Harkin (D-IA), requested that FDA immediately withdraw the …

    • A Federal Court Win on the RLD Theory of Liability; More of Moore Will Likely be Called ForJanuary 9th, 2012

      By Kurt R. Karst –       In what appears to be the first federal court decision on the so-called Reference Listed Drug (“RLD”) theory of liability, Judge Marvin H. Shoob of the U.S. District Court for the Northern District of Georgia (Atlanta Division) recently ruled in Moore …

    • USP Proposes Standards for Probiotic Food IngredientsJanuary 9th, 2012

      By Riëtte van Laack – On January 3, 2012, the U.S. Pharmacopeial Convention (“USP”), a scientific organization that publishes the Food Chemical Codex (“FCC”), an international compendium of quality specifications for food ingredients, announced proposed standards for probiotic food ingredients. The proposed standards will be included …

    • FDA Issues Draft Guidance on Medical Device Appeals ProcessesJanuary 5th, 2012

      By Jeffrey K. Shapiro, Jeffrey N. Gibbs & Jennifer D. Newberger – It is essential to FDA’s proper functioning that stakeholders have a viable appeals process.  This means a process that is timely, transparent, and fair.  A viable appeals process is an essential “check and balance” …

    • D.C. Circuit Affirms Dismissal of Holistic Candler’s Lawsuit and Tosses Out the Whole Ball of WaxJanuary 5th, 2012

      By Susan J. Matthees – Earlier this week, the U.S. Court of Appeals for the District of Columbia Circuit affirmed the U.S. District Court for the District of Columbia’s decision granting FDA’s Motion to Dismiss a lawsuit filed in April 2010 by a group of ear …

    • “Size Matters,” Says FDA, When it Comes to Generic Drug-RLD SamenessJanuary 4th, 2012

      By Kurt R. Karst – In what appears to be a further sign of FDA’s efforts to clamp down on differences between brand-name Reference Listed Drugs (“RLDs”) and their proposed generic counterparts, FDA’s Office of Generic Drugs (“OGD”) is now looking more closely at tablet size …

    • DEA Quotas – Greater Transparency and Predictability NeededJanuary 3rd, 2012

      By James R. Phelps – Over the New Year's Day weekend, The New York Times reported on the shortage of ADHD drugs, with this quote:  “‘We have reached out to the D.E.A. and told them that there are shortage issues,’ said Valerie Jensen, associate director of …

    • HP&M Director to Present at FDLI Food Week 2012January 3rd, 2012

      The Food and Drug Law Institute’s (“FLDI”) annual Food Week Conference is being held in Washington, DC on January 23-26, 2012.  FDLI Food Week features a two-day introduction to food law and regulation, as well as three days of advanced programming on advertising and labeling, …